February 21, 2019
Catalyst Pharmaceuticals Defends Price of LEMS Drug in Letter to Senator Bernie Sanders
Read More
January 9, 2019
The Significant Deals Ahead This Year
Read More
September 5, 2018
NICE Reverses Itself with Positive Recommendation on For Kirin’s XLH Drug Crysvita
Read More
May 30, 2018
Are Orphan Drugs Losing their Luster?
Read More
May 18, 2018
Why Rare Disease Patients Should Worry About the Shifting Discussion from Value to…
Read More
May 7, 2018
ICER Blasts Pricing of Vertex CF Drugs, Vertex Blasts Back Calling Process a…
Read More
April 17, 2018
ICER Says Roche’s Hemophilia A Therapy Improves Health While Lowering Costs
Read More
February 12, 2018
NICE Draft Guidance Says BioMarin’s ERT for Batten Disease Not Cost Effective
Read More
January 17, 2018
ICER Analysis Finds Spark Gene Therapy Priced Too High
Read More
November 22, 2017
Measuring the Value of Therapies for Ultra-Rare Diseases
Read More
November 15, 2017
Duchenne UK Collaborates with Industry to Speed Payer Value Assessments
Read More
November 14, 2017
ICER Issues Modified Framework for Assessing Value of Treatments for Ultra-Rare Diseases
Read More
Load More